Patients with moderate-to-severe chronic pain can be successfully converted from prior opioid therapy to EXALGO (hydromorphone HCl) extended-release tablet, an extended-release (ER) oral formulation of hydromorphone HCl, according to a presentation at the American Pain Society 29th Annual Scientific Meeting. Approved by the US Food and Drug Administration on March 1, 2010, EXALGO is the only ER formulation of hydromorphone ...
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.